158 related articles for article (PubMed ID: 29226628)
1. Modeling of prolactin response following dopamine D
Taneja A; Vermeulen A; Huntjens DRH; Danhof M; De Lange ECM; Proost JH
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226628
[TBL] [Abstract][Full Text] [Related]
2. A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats.
Taneja A; Vermeulen A; Huntjens DRH; Danhof M; De Lange ECM; Proost JH
Eur J Pharmacol; 2016 Oct; 789():202-214. PubMed ID: 27395799
[TBL] [Abstract][Full Text] [Related]
3. Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride in rats.
Taneja A; Vermeulen A; Huntjens DR; Danhof M; De Lange EC; Proost JH
Data Brief; 2016 Sep; 8():1433-7. PubMed ID: 27617278
[TBL] [Abstract][Full Text] [Related]
4. Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human.
Wong YC; Centanni M; de Lange ECM
J Clin Pharmacol; 2019 May; 59(5):731-747. PubMed ID: 30676661
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin.
Ma G; Friberg LE; Movin-Osswald G; Karlsson MO
Br J Clin Pharmacol; 2010 Dec; 70(6):815-24. PubMed ID: 21175437
[TBL] [Abstract][Full Text] [Related]
6. Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans.
Stevens J; Ploeger BA; Hammarlund-Udenaes M; Osswald G; van der Graaf PH; Danhof M; de Lange EC
J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):463-77. PubMed ID: 22791078
[TBL] [Abstract][Full Text] [Related]
7. Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling.
van den Brink WJ; Wong YC; Gülave B; van der Graaf PH; de Lange EC
AAPS J; 2017 Jan; 19(1):274-285. PubMed ID: 27785749
[TBL] [Abstract][Full Text] [Related]
8. Effects of remoxipride and raclopride on prolactin release from clonal pituitary tumour cells.
Nilsson CL; Eriksson E
Pharmacol Toxicol; 1995 Jan; 76(1):85-8. PubMed ID: 7753765
[TBL] [Abstract][Full Text] [Related]
9. Influence of the dosing interval on prolactin release after remoxipride.
Movin-Osswald G; Hammarlund-Udenaes M; Von Bahr C; Eneroth P; Walton-Bowen K
Br J Clin Pharmacol; 1995 May; 39(5):503-10. PubMed ID: 7669486
[TBL] [Abstract][Full Text] [Related]
10. An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment.
Friberg LE; Vermeulen AM; Petersson KJ; Karlsson MO
Clin Pharmacol Ther; 2009 Apr; 85(4):409-17. PubMed ID: 19109590
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.
Nadal R
CNS Drug Rev; 2001; 7(3):265-82. PubMed ID: 11607043
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
Busatto GF; Pilowsky LS; Costa DC; Ell PJ; Verhoeff NP; Kerwin RW
Psychopharmacology (Berl); 1995 Jan; 117(1):55-61. PubMed ID: 7536945
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of remoxipride and raclopride on nigrostriatal and mesolimbic dopaminergic neuronal activity and on the secretion of prolactin and alpha-melanocyte-stimulating hormone.
Eaton MJ; Tian Y; Lookingland KJ; Moore KE
Neuropsychopharmacology; 1992 Nov; 7(3):205-11. PubMed ID: 1326981
[TBL] [Abstract][Full Text] [Related]
14. Target-Site Investigation for the Plasma Prolactin Response: Mechanism-Based Pharmacokinetic-Pharmacodynamic Analysis of Risperidone and Paliperidone in the Rat.
Shimizu S; den Hoedt SM; Mangas-Sanjuan V; Cristea S; Geuer JK; van den Berg DJ; Hartman R; Bellanti F; de Lange EC
Drug Metab Dispos; 2017 Feb; 45(2):152-159. PubMed ID: 27836941
[TBL] [Abstract][Full Text] [Related]
15. Comparative Pharmacology of Risperidone and Paliperidone.
Corena-McLeod M
Drugs R D; 2015 Jun; 15(2):163-74. PubMed ID: 25943458
[TBL] [Abstract][Full Text] [Related]
16. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.
Nakajima S; Uchida H; Bies RR; Caravaggio F; Suzuki T; Plitman E; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Mamo DC; Graff-Guerrero A
Schizophr Bull; 2016 Jan; 42(1):212-9. PubMed ID: 26221049
[TBL] [Abstract][Full Text] [Related]
18. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
Olsen CK; Brennum LT; Kreilgaard M
Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
[TBL] [Abstract][Full Text] [Related]
19. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
Iwata Y; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Plitman E; Chung JK; Mar W; Gerretsen P; Pollock BG; Mulsant BH; Rajji TK; Mamo DC; Graff-Guerrero A
J Clin Psychiatry; 2016 Dec; 77(12):e1557-e1563. PubMed ID: 28086010
[TBL] [Abstract][Full Text] [Related]
20. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects.
Movin-Osswald G; Hammarlund-Udenaes M
J Pharmacol Exp Ther; 1995 Aug; 274(2):921-7. PubMed ID: 7636755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
